821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab

• Edith A Perez,
• Andrew Luo,
• Anthony Lucas,
• Han K Kim,
• Paul D Ponath,
• Katelynn A McEachin,
• Karla A Henning,
• Shelley E Ackerman,
• Steven J Chapin,
• Michael N Alonso,
• Cecelia I Pearson,
• David Omstead

Affiliations

Edith A Perez

Bolt Biotherapeutics, Inc., Redwood City, CA, USA

Andrew Luo

Bolt Biotherapeutics, Inc., Redwood City, CA, USA

Anthony Lucas

Bolt Biotherapeutics, Inc., Redwood City, CA, USA

Han K Kim

1Bolt Biotherapeutics, Redwood City, CA, USA

Paul D Ponath

1Bolt Biotherapeutics, Redwood City, CA, USA

Katelynn A McEachin

1Bolt Biotherapeutics, Redwood City, CA, USA

Karla A Henning

1Bolt Biotherapeutics, Redwood City, CA, USA

Shelley E Ackerman

1Bolt Biotherapeutics, Redwood City, CA, USA

Steven J Chapin

1Bolt Biotherapeutics, Redwood City, CA, USA

Michael N Alonso

1Bolt Biotherapeutics, Redwood City, CA, USA

Cecelia I Pearson

Bolt Biotherapeutics, Inc., Redwood City, CA, USA

David Omstead

Bolt Biotherapeutics, Inc., Redwood City, CA, USA